Sterile Cleanroom Wipes
VAI?s Sterile Cleanroom Wipers use innovative manufacturing technologies and a single source, dedicated supply chain allows for traceablility.
VAI’s Sterile Cleanroom Wipes use innovative manufacturing technologies, and the single source dedicated supply chain allow for the vertical manufacturing process to be completely traceable from start to finish.
VAI’s wipes are knitted with continuous monofilament polyester and are cut using a “focused edge” cutting technology. This eliminates the risk of particulates being introduced into classified areas, by improving the edge over traditional laser cutting.
All wipes are quality assurance tested and released to specifications defined by IEST and ASTM methods.
VAI’s wipes are made with one material (dry or saturated) for easy inexpensive validation and consistency throughout your manufacturing areas. All versions of dry or saturated wipes are manufactured under cGMP’s, are lot traceable and validated.
VAI’s high quality wipes are available in WipeDown® dry wipes, Procees2Wipe® (USP IPA and WFI Quality Water), HYPO-CHLOR® WFI formula in 0.25%, 0.52%, and 5.25%, STERI-PEROX® WFI formula 3% and 6%, DECON-Clean® RTU residue remover, individually packaged Alcoh Wipes®, STEEL-BRIGHT® Wipes and DAS® Wipes.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
